Literature DB >> 35233795

Gut dysbiosis and long COVID-19: Feeling gutted.

Panagiotis Giannos1, Konstantinos Prokopidis2.   

Abstract

Entities:  

Mesh:

Year:  2022        PMID: 35233795      PMCID: PMC9088471          DOI: 10.1002/jmv.27684

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   20.693


× No keyword cloud information.
To the Editor, COVID‐19 is primarily a respiratory illness, however, there is compelling evidence proposing a lung‐gut axis involved in the disease. We explored emerging evidence suggesting a possible link between dysbiosis of the gut microbiota and long‐term complications from COVID‐19. Emerging evidence has suggested that the pathology of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) may in part be explained by microbial species, contributing to the inflammatory phenotype commonly seen in patients with coronavirus disease (COVID‐19). , Indeed, dysbiosis of the gut microbiota has been associated with poor clinical outcomes in mechanically ventilated COVID‐19 patients. Specifically, Wu et al. observed elevated Granulicatella and Rothia mucilaginosa in the gut microbiome of COVID‐19 hospitalized patients when compared to healthy individuals. Additionally, increased Burkholderia cepacia complex, Staphylococcus epidermidis, Mycoplasma hominis, and Mycroplasma orale species have been observed in severely ill COVID‐19 patients as opposed to mildly affected ones. These findings hint at a possible yet prominent link between gut microbiota and SARS‐CoV‐2 repercussions, which may also be related to the imminent occurrence of long‐term COVID‐19 complications. Contemporary research has revealed a disruption of the gut microbiota in stool samples of SARS‐CoV‐2 patients that may explain the well‐described cytokine storm‐induced ramifications post‐infection. Interestingly, fecal transplantation may regenerate gut microbiota diversity, bolstering the respiratory system of patients suffering from COVID‐19. Considering that long‐term complications following recovery from SARS‐CoV‐2 persistently exhibit a damaged microbial microenvironment compared to uninfected controls, these changes may hint at alterations in the patients' microbiome. We describe recently published data on the relationship of the long COVID‐19 phenomenon with gut microbiota dysbiosis, providing a mechanistic insight. Our aim is to raise awareness of the impact SARS‐CoV‐2 imposes on public health that in part may be explained through a gut‐lung axis cascade. The depletion of immunomodulatory microbiota from severe SARS‐CoV‐2 infection may prolong physiological repercussions (i.e., lung injury) during long COVID‐19, induced by systemic inflammation. The recent study by Chen et al. showed significant reductions of microbial diversity in patients with COVID‐19 during a 6‐month follow‐up, as opposed to the aseptic group. Particularly, following acute (30 days) and prolonged (3 months) SARS‐CoV‐2 recovery, suppression of anti‐inflammatory bacteria such as Faecalibacterium prausnitzii, Eubacterium rectale, and Bifidobacterium adolescentis, and enrichment of pathogens, including Rothia, Erysipelatoclostridium, Ruminococcus gnavus, Ruminococcus torques, and Bacteroides dorei have been observed. , These changes may underlie the association between lower gut microbiota diversity and higher C‐reactive protein levels in long COVID‐19 patients (Figure 1).
Figure 1

Lung–gut axis microbial dysbiosis in long SARS‐CoV‐2. CRP, C‐reactive protein

Lung–gut axis microbial dysbiosis in long SARS‐CoV‐2. CRP, C‐reactive protein The substantial increase of pathogenic bacteria concomitantly with decreased anti‐inflammatory microbiota, advocates for a prominent link between sustained intestinal inflammation during COVID‐19 infection. Therefore, these alterations may subsequently lead to prolonged SARS‐CoV‐2 recovery, campaigning for the importance of a favorable gut microenvironment. Clinical trials experimenting with supplementation of anti‐inflammatory bacterial species and/or fecal transplantation may be imperative to accelerate gut microbiota restoration and long COVID‐19 rehabilitation.

AUTHOR CONTRIBUTIONS

Panagiotis Giannos made an investigation plan and drafted the manuscript. Konstantinos Prokopidis conceived the idea and revised the manuscript critically for important intellectual content.

CONFLICTS OF INTEREST

The authors declare the absence of any commercial or financial relationships that could be construed as a potential conflicts of interest.
  11 in total

1.  Rapid resolution of COVID-19 after faecal microbiota transplantation.

Authors:  Jarosław Biliński; Katarzyna Winter; Marcin Jasiński; Anna Szczęś; Natalia Bilinska; Benjamin H Mullish; Ewa Małecka-Panas; Grzegorz W Basak
Journal:  Gut       Date:  2021-07-06       Impact factor: 23.059

2.  Gut Microbiota May Not Be Fully Restored in Recovered COVID-19 Patients After 3-Month Recovery.

Authors:  Yu Tian; Kai-Yi Sun; Tian-Qing Meng; Zhen Ye; Shi-Meng Guo; Zhi-Ming Li; Cheng-Liang Xiong; Ying Yin; Hong-Gang Li; Li-Quan Zhou
Journal:  Front Nutr       Date:  2021-05-13

3.  Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19.

Authors:  Yun Kit Yeoh; Tao Zuo; Chun Kwok Wong; Grace Chung-Yan Lui; Fen Zhang; Qin Liu; Amy Yl Li; Arthur Ck Chung; Chun Pan Cheung; Eugene Yk Tso; Kitty Sc Fung; Veronica Chan; Lowell Ling; Gavin Joynt; David Shu-Cheong Hui; Kai Ming Chow; Susanna So Shan Ng; Timothy Chun-Man Li; Rita Wy Ng; Terry Cf Yip; Grace Lai-Hung Wong; Francis Kl Chan; Paul Ks Chan; Siew C Ng
Journal:  Gut       Date:  2021-01-11       Impact factor: 23.059

4.  Temporal association between human upper respiratory and gut bacterial microbiomes during the course of COVID-19 in adults.

Authors:  Rong Xu; Renfei Lu; Tao Zhang; Qunfu Wu; Weihua Cai; Xudong Han; Zhenzhou Wan; Xia Jin; Zhigang Zhang; Chiyu Zhang
Journal:  Commun Biol       Date:  2021-02-18

5.  Characterization of respiratory microbial dysbiosis in hospitalized COVID-19 patients.

Authors:  Huanzi Zhong; Yanqun Wang; Zhun Shi; Lu Zhang; Huahui Ren; Weiqun He; Zhaoyong Zhang; Airu Zhu; Jingxian Zhao; Fei Xiao; Fangming Yang; Tianzhu Liang; Feng Ye; Bei Zhong; Shicong Ruan; Mian Gan; Jiahui Zhu; Fang Li; Fuqiang Li; Daxi Wang; Jiandong Li; Peidi Ren; Shida Zhu; Huanming Yang; Jian Wang; Karsten Kristiansen; Hein Min Tun; Weijun Chen; Nanshan Zhong; Xun Xu; Yi-Min Li; Junhua Li; Jincun Zhao
Journal:  Cell Discov       Date:  2021-04-13       Impact factor: 10.849

6.  SARS-CoV-2 infection reduces human nasopharyngeal commensal microbiome with inclusion of pathobionts.

Authors:  M Nazmul Hoque; Md Murshed Hasan Sarkar; M Shaminur Rahman; Shahina Akter; Tanjina Akhtar Banu; Barna Goswami; Iffat Jahan; M Saddam Hossain; A K Mohammad Shamsuzzaman; Tasnim Nafisa; M Maruf Ahmed Molla; Mahmuda Yeasmin; Asish Kumar Ghosh; Eshrar Osman; S K Saiful Alam; Mohammad Samir Uzzaman; Md Ahashan Habib; Abu Sayeed Mohammad Mahmud; Keith A Crandall; Tofazzal Islam; Md Salim Khan
Journal:  Sci Rep       Date:  2021-12-15       Impact factor: 4.379

7.  Depicting SARS-CoV-2 faecal viral activity in association with gut microbiota composition in patients with COVID-19.

Authors:  Tao Zuo; Qin Liu; Fen Zhang; Grace Chung-Yan Lui; Eugene Yk Tso; Yun Kit Yeoh; Zigui Chen; Siaw Shi Boon; Francis Kl Chan; Paul Ks Chan; Siew C Ng
Journal:  Gut       Date:  2020-07-20       Impact factor: 23.059

8.  Six-month follow-up of gut microbiota richness in patients with COVID-19.

Authors:  Yanfei Chen; Silan Gu; Yunbo Chen; Haifeng Lu; Ding Shi; Jing Guo; Wen-Rui Wu; Ya Yang; Yongtao Li; Kai-Jin Xu; Cheng Ding; Rui Luo; Chenjie Huang; Ling Yu; Min Xu; Ping Yi; Jun Liu; Jing-Jing Tao; Hua Zhang; Longxian Lv; Baohong Wang; Jifang Sheng; Lanjuan Li
Journal:  Gut       Date:  2021-04-08       Impact factor: 23.059

9.  Altered oral and gut microbiota and its association with SARS-CoV-2 viral load in COVID-19 patients during hospitalization.

Authors:  Yongjian Wu; Xiaomin Cheng; Guanmin Jiang; Huishu Tang; Siqi Ming; Lantian Tang; Jiahai Lu; Cheng Guo; Hong Shan; Xi Huang
Journal:  NPJ Biofilms Microbiomes       Date:  2021-07-22       Impact factor: 7.290

View more
  4 in total

Review 1.  Diabetes and SARS-CoV-2-Is There a Mutual Connection?

Authors:  Anna P Jedrzejak; Edyta K Urbaniak; Jadwiga A Wasko; Natalia Ziojla; Malgorzata Borowiak
Journal:  Front Cell Dev Biol       Date:  2022-06-13

2.  Spotlight on Early COVID-19 Research Productivity: A 1-Year Bibliometric Analysis.

Authors:  Panagiotis Giannos; Konstantinos S Kechagias; Konstantinos Katsikas Triantafyllidis; Matthew E Falagas
Journal:  Front Public Health       Date:  2022-05-31

3.  Graves' disease following vaccination against SARS-CoV-2: A systematic review of the reported cases.

Authors:  Konstantinos Katsikas Triantafyllidis; Panagiotis Giannos; Dimitra Stathi; Konstantinos S Kechagias
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-27       Impact factor: 6.055

4.  Kynurenine serves as useful biomarker in acute, Long- and Post-COVID-19 diagnostics.

Authors:  Daniel Alexander Bizjak; Manfred Stangl; Nikolaus Börner; Florian Bösch; Joachim Durner; Gergana Drunin; Jasmine-Leonike Buhl; Dietmar Abendroth
Journal:  Front Immunol       Date:  2022-09-23       Impact factor: 8.786

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.